Holen Sie sich die Stockscreener-App
316.49
2.50%
7.71
Handel nachbörslich:
316.49
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$308.78
Offen:
$309.74
24-Stunden-Volumen:
1.03M
Relative Volume:
0.74
Marktkapitalisierung:
$60.39B
Einnahmen:
$328.68B
Nettoeinkommen (Verlust:
$2.55B
KGV:
24.28
EPS:
13.0349
Netto-Cashflow:
$1.56B
1W Leistung:
-2.99%
1M Leistung:
-0.49%
6M Leistung:
-3.19%
1J Leistung:
+9.13%
1-Tages-Spanne:
$308.51
$316.98
1-Wochen-Bereich:
$304.45
$325.88
52-Wochen-Spanne:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
316.49 | 61.36B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
886.47 | 102.78B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
225.75 | 54.56B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
85.20 | 9.85B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
0.76 | 718.95M | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Benzinga
Cencora (COR) ex-officer lines up new stock sale - Stock Titan
Cencora (COR) Stock Forecast and Price Target 2026 $COR - MarketBeat
Cencora stock heads into the open after a 0.1% dip - ad-hoc-news.de
Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings? - Yahoo Finance
Cencora Inc. stock dips after RBC reiterates cautious price target - ad-hoc-news.de
Is Cencora Stock Underperforming the Dow? - Yahoo Finance
Cencora stock price target maintained at $330 by RBC Capital By Investing.com - Investing.com Australia
Cencora stock heads into the open after a modest decline - ad-hoc-news.de
Cencora stock holds firm after RBC keeps $330 target - ad-hoc-news.de
Cencora Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cencora stock price target maintained at $330 by RBC Capital - Investing.com Canada
Cencora, Inc. (COR) Stock Analysis: Robust Growth in Medical Distribution with an 11.59% Upside Potential - DirectorsTalk Interviews
Cencora Inc. stock gains on solid fiscal 2026 momentum - ad-hoc-news.de
Why Cencora (COR) Is Getting Attention Today - simplywall.st
Cencora’s New Cell and Gene Services Might Change The Case For Investing In Cencora (COR) - simplywall.st
Cencora Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now - Yahoo Finance
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Former Cencora (NYSE: COR) leader lines up another stock sale - Stock Titan
Cencora Inc. stock gains on new cell and gene therapy service and strong guidance - ad-hoc-news.de
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Cencora Launches Cell and Gene Therapy Enablement for Health Systems - Yahoo Finance
Cencora (COR) Unveils Cell And Gene Therapy Enablement Service - simplywall.st
What Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders - Yahoo Finance
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen - Yahoo Finance
Cencora Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs - BioBuzz
Artisan Sold Cencora (COR) as Earnings Momentum Slowed - Yahoo Finance
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora (NYSE: COR) executive sells 985 shares in preset plan - Stock Titan
Cencora Launches Cell and Gene Therapy Enablement Service Through Accelerate Pharmacy Solutions - marketscreener.com
Cencora Inc. stock reflects insider sale plans and steady growth outlook - ad-hoc-news.de
Former Cencora (NYSE: COR) executive lines up stock sale after restricted shares vest - stocktitan.net
Cencora, Inc. (COR) Stock Analysis: A Healthcare Powerhouse with 14.68% Potential Upside - DirectorsTalk Interviews
Cencora (COR) Q2 2026 Earnings Call Transcript - Fortune
Cencora Executive VP & Chief Legal Officer Elizabeth Campbell Sells 37% Of Holding - simplywall.st
Cencora (COR) Earnings History & Trends - 24/7 Wall St.
Elizabeth S Campbell Takes Money Off The Table, Sells $3.66M In Cencora Stock - benzinga.com
Is Cencora (COR) Still Undervalued Following Its Board Resignation News? - sahmcapital.com
Cencora, Inc. (COR) Stock Analysis: A Healthcare Giant With A 16% Upside Potential - DirectorsTalk Interviews
Paralel Advisors LLC Purchases New Position in Cencora, Inc. $COR - MarketBeat
Silvant Capital Management LLC Invests $11.93 Million in Cencora, Inc. $COR - MarketBeat
$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Sahm
Fairtree Asset Management Pty Ltd Makes New $1.77 Million Investment in Cencora, Inc. $COR - MarketBeat
B. Metzler seel. Sohn & Co. AG Invests $9.62 Million in Cencora, Inc. $COR - MarketBeat
Algebris UK Ltd. Invests $969,000 in Cencora, Inc. $COR - MarketBeat
Cencora (NYSE:COR) Healthcare Growth Story Gains Fresh Momentum - Kalkine Media
Quartz Partners LLC Buys Shares of 15,650 Cencora, Inc. $COR - MarketBeat
United Bank Purchases New Stake in Cencora, Inc. $COR - MarketBeat
Shepherd Financial Partners LLC Takes Position in Cencora, Inc. $COR - MarketBeat
Meeder Advisory Services Inc. Purchases New Stake in Cencora, Inc. $COR - MarketBeat
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):